Research

Hormonal

GLP-1 receptor agonists (GLP-1RAs) induce significant weight loss in adults with obesity or overweight by acting on the central nervous system to increase satiety and on the gastrointestinal tract to delay gastric emptying.

GLP-1 medications (like Semaglutide or Tirzepatide) are highly effective for weight loss, often achieving 15-25% body weight reduction in clinical trials. They work by reducing appetite and slowing digestion. These are prescription medications, not supplements. They require long-term use to maintain weight loss, as stopping often leads to regain. They are generally safe but can cause gastrointestinal side effects. Consult a doctor to see if you are a candidate.

StrongSupportsVERY_HIGH confidence
GLP-1RA 的减重机制包括:(1) 作用于中枢,抑制食欲,增加下丘脑弓状核饱食信号的水平,并降低抑制信号,从而增强饱腹感,减少热量摄入;(2) 作用于胃肠道,延缓胃排空和胃肠蠕动,减少胃泌素刺激的胃酸分泌。
Jun Yin et al. · Chinese Science Bulletin (Chinese Version) · 2024

Why this rating

The paper cites multiple large-scale, randomized, double-blind, placebo-controlled clinical trials (e.g., STEP 1, SURMOUNT-1) with significant sample sizes.

Source

The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity

Jun Yin et al. · Chinese Science Bulletin (Chinese Version) · 2024

narrative_review
Read the paper

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →